CYP2C19 and Stroke: In the secondary prevention of stroke, the commonly used antiplatelet drug clopidogrel needs to be converted into its active metabolite by hepatic cytochrome p450 (CYP) to take effect, and decreased effects of clopidogrel were observed in carriers of CYP2C19 loss-of-function allele (34).